Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
- Denka Seiken to Start Development of Mass Production Technology for Therapeutic Oncolytic Virus for Cancer Therapy
May 13, 2015
- Ethical Drug Sales Down 5.2% in March: Crecon Report
May 13, 2015
- Shionogi Logs Record Ordinary Profit on Weaker Yen, ViiV Dividends
May 12, 2015
- Sumitomo Dainippon’s Profits Slide as Japan Sales Flounder
May 12, 2015
- Astellas Withdraws NDA for Nateglinide in Combination with DPP-4 Inhibitors
May 12, 2015
- Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
- MTPC Sees Sales Rise for Remicade in FY2015, Mulls M&A under 5-Year Biz Plan
May 11, 2015
- MTPC Sales Up Slightly as Gilenya, Invokana Royalties Eclipse Japan Dip
May 11, 2015
- Takeda, NCC Join Hands on Cancer Drug Research
May 11, 2015
- Takeda to Return Latuda Rights in Europe to Sumitomo Dainippon
May 8, 2015
- Takecab Tops in GP and HP Markets for 3rd Month in a Row in March: Anterio Ranking
May 8, 2015
- Oncolys Initiates PI Trial of Novel Anticancer Drug in Patients with Solid Cancers in the US
May 8, 2015
- US Drug Spending Spikes in 2014 Lifted by Cancer, Hepatitis C Medicines: IMS
May 7, 2015
- PhRMA Member Companies Invest US$51.2 Billion in New Drug R&D in 2014
May 7, 2015
- US Sales of Abilify Rise 2.4% in January-March: Otsuka Holdings
May 7, 2015
- Zeria Cuts FY2014 Forecasts, to Lose 40% of Estimated Profits
May 7, 2015
- Fujifilm Holdings Acquires Cellular Dynamics International through Tender Offer
May 7, 2015
- Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
- Takeda Agrees to Pay US$2.37 Billion to Settle Actos Suits, Braces for 1st Net Loss
May 1, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…